Association of response to programmed death receptor 1 (PD-1) blockade with pembrolizumab (MK-3475) with an interferon-inflammatory immune gene signature.Antoni Ribas, Adil Daud, Caroline Robert et al.|Journal of Clinical Oncology|2015Cited by 200
Efficacy and safety of the anti-PD-1 monoclonal antibody MK-3475 in 411 patients (pts) with melanoma (MEL).Antoni Ribas, Caroline Robert, Roxana Dronca et al.|Journal of Clinical Oncology|2014Cited by 130
Three-year overall survival for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001.Caroline Robert, F. Stephen Hodi, Antoni Ribas et al.|Journal of Clinical Oncology|2016Cited by 107
Temozolomide plus thalidomide in patients with brain metastases from melanomaWen‐Jen Hwu, Alan N. Houghton, Eric Lis et al.|Cancer|2005Cited by 102
Clinical efficacy and correlation with tumor PD-L1 expression in patients (pts) with melanoma (MEL) treated with the anti-PD-1 monoclonal antibody MK-3475.Richard Kefford, Wen‐Jen Hwu, Antoni Ribas et al.|Journal of Clinical Oncology|2014Cited by 91